These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 14709929)

  • 1. Randomized clinical trial: myths around elementary statistical principles.
    Edler L; Kopp-Schneider A
    Onkologie; 2003 Dec; 26(6):551-6. PubMed ID: 14709929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistical principles: myths or facts?
    Sylvester R
    Onkologie; 2003 Dec; 26(6):520-1. PubMed ID: 14709923
    [No Abstract]   [Full Text] [Related]  

  • 3. Statistical trial designs and clinical practice: are they compatible?
    Punt CJ
    Onkologie; 2003 Dec; 26(6):518-9. PubMed ID: 14709922
    [No Abstract]   [Full Text] [Related]  

  • 4. Reliably basing conclusions on subgroups of randomized clinical trials.
    Koch A; Framke T
    J Biopharm Stat; 2014; 24(1):42-57. PubMed ID: 24392977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Confirmatory clinical trials with an adaptive design.
    Koch A
    Biom J; 2006 Aug; 48(4):574-85. PubMed ID: 16972708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent.
    Serebruany VL
    Cardiology; 2011; 120(3):169-71. PubMed ID: 22418766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology.
    Barton S; Peckitt C; Sclafani F; Cunningham D; Chau I
    Eur J Cancer; 2015 Dec; 51(18):2732-9. PubMed ID: 26608121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response adaptive randomization procedures in seamless phase II/III clinical trials.
    Zhu H; Piao J; Lee JJ; Hu F; Zhang L
    J Biopharm Stat; 2020; 30(1):3-17. PubMed ID: 31454295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New designs for basket clinical trials in oncology.
    Simon R
    J Biopharm Stat; 2018; 28(2):245-255. PubMed ID: 28877003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of randomized controlled trials.
    Peduzzi P; Henderson W; Hartigan P; Lavori P
    Epidemiol Rev; 2002; 24(1):26-38. PubMed ID: 12119853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional consistency and sample size considerations in a multiregional equivalence trial.
    Wu SC; Xu JF; Zhang XJ; Li ZW; He J
    Pharm Stat; 2020 Nov; 19(6):897-908. PubMed ID: 32716135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistics in oncology.
    Land SR; Abrams J; Buyse M; Chappell RJ
    J Clin Oncol; 2008 Aug; 26(22):3668. PubMed ID: 18669450
    [No Abstract]   [Full Text] [Related]  

  • 13. How practical are adaptive designs likely to be for confirmatory trials?
    Gould AL
    Biom J; 2006 Aug; 48(4):644-9; discussion 660-2. PubMed ID: 16972716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A note on statistical power in multi-site randomized trials with multiple treatments at each site.
    Liu XS
    Br J Math Stat Psychol; 2014 May; 67(2):231-47. PubMed ID: 23710937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Many multicenter trials had few events per center, requiring analysis via random-effects models or GEEs.
    Kahan BC; Harhay MO
    J Clin Epidemiol; 2015 Dec; 68(12):1504-11. PubMed ID: 25985892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Introduction to the statistical aspects of planning clinical oncologic phase III studies].
    Sylvester R; Minder CE
    Urologe A; 1995 Sep; 34(5):367-73. PubMed ID: 7483152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials.
    Bhattacharya S; Fyfe G; Gray RJ; Sargent DJ
    J Clin Oncol; 2009 Dec; 27(35):5958-64. PubMed ID: 19826121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events.
    Potthoff RF; Halabi S
    Pharm Stat; 2015; 14(4):273-83. PubMed ID: 25894200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methodological issues of randomized controlled trials for the evaluation of reproductive health interventions.
    Villar J; Carroli G
    Prev Med; 1996; 25(3):365-75. PubMed ID: 8781015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An urn model for odds-ratio-based response-adaptive phase III clinical trials for two or more treatments.
    Basak GK; Biswas A; Volkov S
    J Biopharm Stat; 2009 Sep; 19(5):838-56. PubMed ID: 20183447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.